Crispr Therapeutics Ag (CRSP)
$85.90
0.76 (0.89%)
CRSP Stock Quote Delayed 30 Minutes
Previous Close
$85.90
Market Cap
4.02B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
643,300
Day's Range
83.40 - 87.71
52-Week Range
32.30 - 105.12
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
CRISPR Therapeutics Stock Is a Strong Buy on the Dip
CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.
How to Find the Top Stocks in the Hottest Sectors
Here's how a sector fund can help you find top stocks in sizzling sectors. They’re a great place to start, especially when you want to gain exposure to a specific hypergrowth trend.
Is CRISPR Therapeutics Worth It Without Drugs?
We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.
The Future Could Be Soon for Crispr Therapeutics
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
3 Reasons to Go Long Crispr Therapeutics
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
CRISPR Therapeutics Is a Worthwhile Investment in Transformative Science
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Consider Adding New Positions in U.S. Cannabis Stocks
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
